linjc16/ctgov huggingface dataset:
Effects of Exercise Poles on Older Adults During Exercise Walking

Study Overview
=================
Brief Summary
-----------------
This study uses a patented type of exercise poles, developed to assist runners rehabilitating from lower body injuries. These poles may offer older adults improved stability, reduced fear of falling, and lessened lower body pain when exercise walking.

Detailed Description
-----------------
Phase 1 (being concluded as of Feb 2002) used 18 older adults to investigate prototype versions of the running poles. Preliminary results, after 3 months of testing, indicate the poles are safe and effective. Phase 2 will use improved versions of the poles, which are currently in development, with a group of around 125-150 subjects over a longer length of time (12 months). Changes in walking gait quality, balance, strength, body composition, exercise adherence, and subjective perceptions of wellness will be assessed before, during, and after the 12 month exercise session.

Official Title
-----------------
Impact of Running Poles on Older Adult Exercise Walking

Conditions
-----------------
Movement Disorders, Aging

Intervention / Treatment
-----------------
* Device: Exercise poles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 65-80 Normal gait Exclusion Criteria: Inability to walk continuously for 5 minutes Contraindication from a personal physician Height over 6'2 or weight over 200 lbs (due to limitations of existing pole design) Mild to severe cognitive impairment

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Exercise poles|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fall-Prevention, Balance, Musculoskeletal Systems, Protective Devices, Gait, Equilibrium, Accidental Falls, Frail Elderly
Learning Curve of Optiscope by Anesthesia Providers

Study Overview
=================
Brief Summary
-----------------
Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope for endotracheal intubation. This study will investigate learning curve of Optiscope by anesthesia providers.

Official Title
-----------------
Learning Curve of Optiscope by Anesthesia Providers

Conditions
-----------------
Intubation, Intratracheal

Intervention / Treatment
-----------------
* Device: intubation using optiscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient who is scheduled general anesthesia for elective surgery Exclusion Criteria: patient who is anticipated difficult airway patient who is needed rapid sequence induction Cervical injury

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: intubation using optiscope<br>The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery. | Device: intubation using optiscope<br>* Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to intubation | Time to intubation (from optiscope insertion to the detection of end tidal CO2) will be recorded. If time to inubation is longer than 180 s or pulse oxymetry is lower than 94%, mask ventilation will be performed. If intubation is not successful within 3 trials, it will be performed using direct laryngoscope. | intubation period |
Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa

Study Overview
=================
Brief Summary
-----------------
Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength. We are investigating whether a hormone that is naturally produced by the human body, called growth hormone, can help strengthen the bones of women with this type of disordered eating.

Detailed Description
-----------------
Twelve week study Eight visits, six of which can be conducted at your home physician's office Two bone density scans Hormonal and nutritional evaluations

Official Title
-----------------
Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa

Conditions
-----------------
Anorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders

Intervention / Treatment
-----------------
* Drug: Recombinant Human Growth Hormone
* Drug: Placebo for Recombinant Human Growth Hormone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women between 14 to 45 years with anorexia nervosa Exclusion Criteria: pregnancy previous history of malignancy. oral contraceptive pills or other hormones within last 8 - 12 weeks medications known to affect bone within last 12 weeks fracture within last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Treatment with rHGH | Drug: Recombinant Human Growth Hormone<br>* Dosage increased in steps for first four weeks. Self injection qd x 12 weeks<br>* Other names: Nutropin AQ;|
| Placebo Comparator: 2<br>Treatment with Placebo | Drug: Placebo for Recombinant Human Growth Hormone<br>* Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks<br>* Other names: Placebo for Nutropin AQ;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone Metabolism | Change in the marker of bone formation, N-terminal pro peptide of type 1 procollagen (P1NP) levels, between baseline and 12 weeks | Baseline, 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IGF-1 Level | Change in IGF-1 level between baseline and 12 weeks | Baseline, 12 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anorexia Nervosa, Eating disorder, Bone, Growth hormone, Osteopenia, Osteoporosis
Serratus Plane Block After Minimally Invasive Mitral Valve Repair

Study Overview
=================
Brief Summary
-----------------
Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups. The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually. The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.

Official Title
-----------------
Serratus Plane Block After Minimally Invasive Mitral Valve Repair

Conditions
-----------------
Minimal Invasive Cardiac Surgery, Minimal Invasive Cardiac Surgery Mitral Valve Surgery, Serratus Anterior Plane Block

Intervention / Treatment
-----------------
* Drug: Continous SAPB (Ropivacain)
* Other: institutional standard of care pain medication protocol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Planned minimal invasive mitral valve repair via right anterior thoracotomy Exclusion Criteria: Pregenancy Opioid abuse Historyof chronic pain Allergy to local anaesthetics (in this case ropivacain) Patients who simultaneously participate in another interventional clinical trial, unless the Principal Investigators of the clinical trials give consent by mutual agreement Soft tissue infection in the area of the procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Continuous SAPB<br>postoperative serratus-anterior-plane-block 20ml Ropivacain 0,75%, pain catheter with continous administered Ropivacain (5ml/h 0,2% for 48h) | Drug: Continous SAPB (Ropivacain)<br>* postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h<br>Other: institutional standard of care pain medication protocol<br>* institutional standard of care pain medication protocol<br>|
| Placebo Comparator: Placebo<br>standard of care | Other: institutional standard of care pain medication protocol<br>* institutional standard of care pain medication protocol<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesic effect of SAPB in MIC-MVR | Numeric Pain Rating Scale | within 48 hours after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesic effect of SAPB in MIC-MVR | Total opioid consumption in the intensive care unit | within 48 hours after surgery |
Optimizing the Approach of Mobile Application Use to Improve Medication Adherence in Patients With Hypertension

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to determine the effectiveness of using a custom-designed mobile application to improve blood pressure (BP) and promote adherence to antihypertensive medication regimens. This was a prospective, multicenter, randomized controlled trial. Patients were randomized to an intervention or control group for three months. Antihypertensive medication refill history was assessed three months before, during and three months after the study period. Continuous outcome measures investigated were systolic/diastolic BP and medication refill history, using the cumulative medication gap (CMG) score.

Official Title
-----------------
Optimizing the Approach of Mobile Application Use to Improve Medication Adherence in Patients With Hypertension

Conditions
-----------------
Medication Adherence, Hypertension

Intervention / Treatment
-----------------
* Other: Mobile application (BP-n-Me)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years of age Diagnosed with hypertension as evidenced by diagnosis codes or chart documentation Prescribed at least one antihypertensive for a minimum of three months prior to enrollment Have access to an Android mobile device with data capabilities Consent to using the application on their device Exclusion Criteria: Do not read or speak English Unable to read and sign the informed consent or Health Insurance Privacy and Accountability Act (HIPAA) waiver Too ill or cognitively impaired to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Other: Intervention<br>Mobile application intervention | Other: Mobile application (BP-n-Me)<br>* The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medication adherence | This was assessed based on cumulative medication gap (CMG) | 6 months | 
| Blood pressure | This was assessed by measuring the change of systolic and diastolic blood pressure | 6 months |
Broad Effectiveness: Study With Aripiprazole

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders

Official Title
-----------------
Broad Effectiveness: Study With Aripiprazole

Conditions
-----------------
Schizophrenia, Schizoaffective Disorder

Intervention / Treatment
-----------------
* Drug: Aripiprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients with Schizophrenia or Schizoaffective Disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Aripiprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Assessments |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Assessments |  |  |
Human Papilloma Virus (HPV) Knowledge and Attitudes and the Role of (SES) Socioeconomic Status and Ethnicity

Study Overview
=================
Brief Summary
-----------------
This is a survey study to assess the vaccination knowledge and attitudes of women in an inner city Gynecology clinic. Results of this study will help determine which factors influence vaccination knowledge and attitudes. This may help improve future vaccination tools.

Official Title
-----------------
The Role of Socioeconomic Status and Ethnicity in Influencing HPV Vaccine Knowledge and Attitudes in Adult Women

Conditions
-----------------
HPV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all women attending gynecology clinic Exclusion Criteria: none
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPV, HPV vaccine
MRI Imaging of Chronobiologic Abnormalities in Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to identify and understand patterns of brain activity when people are depressed. The study will use an imaging method called Magnetic Resonance Imaging (MRI) which does not involve any exposure to radioactivity or radioactive substances.

Detailed Description
-----------------
The purpose of the study is to identify and understand patterns of brain activity when people are depressed. The study will use an imaging method called Magnetic Resonance Imaging (MRI) which does not involve any exposure to radioactivity or radioactive substances.

Official Title
-----------------
MRI Imaging of Chronobiologic Abnormalities in Depression

Conditions
-----------------
Depression

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: WEIGHT: less than or at 20% over ideal weight, as specified in the 1983 Metropolitan Height and Weight Tables. Patients who deviate from these ranges may be reviewed on an individual basis by the Investigator. This criterion is necessary because of mechanical limitations in fitting overweight individuals into the scanner, and the risk of excessive claustrophobic responses if tightly constricted. HEALTH: healthy, ambulatory normal or depressed adults Exclusion Criteria: Presence of aneurysm clips, cardiac pacemakers, cochlear implants, metal in the eyes, and implanted insulin pumps. Evidence of significant hepatic, gastrointestinal, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular system abnormalities. Pregnancy. Patients with a known or suspected history of alcohol or drug misuse and/or a positive urine drug screen. Patients who are unwilling or unable to abide by the requirements of the study or who violate the prohibitions and restrictions of the study. Any condition which would make the patient, in the opinion of the Investigator, unsuitable for the study. Patients on antidepressants may not be taking any other medication, except at the discretion of the investigator. Untreated depressed or healthy subjects must be free of all medications except as approved by the investigator. Patients with serious medical illness, history or signs/symptoms of lumbar spine/disc disease or significant laboratory findings. Patients who present significant suicide risk, e.g. with a history of highly impulsive suicide attempts.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy volunteers<br> | |
| Depressed patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI, depression, imaging
Homemade Fenestrated Physician-modified Stent-grafts for Arch Aortic Degenerative Aneurysm

Study Overview
=================
Brief Summary
-----------------
The aim was to evaluate early and medium-term outcomes of single and double fenestrated physician-modified endovascular grafts (PMEGs) for endovascular aortic arch degenerative aneursym repair. The evolution of stent-graft technology recently has meant the development of custom-made branched stent-grafts to achieve total endovascular aortic arch repair for high-risks patients. The disadvantages of custom-made include manufacture and deliver times for urgent cases and the associated high costs. Unfortunately there is also a high rate of embolization associated with this approach probably related to the complexity of deploying a multi-branched unibody stent-graft. A further alternative is physician modified endografts (PMEGs) for zone 0 TEVAR involving the deployment of a conventional stent-graft device ex-vivo, fashioning of customized fenestrations (for supra aortic trunk) and re-constrainment into the delivery system. The authors have previously shown the feasability in vitro and they have reported their experience for arch aortic lesion. The aim of this study is to evaluate the outcomes for aortic arch degenerative aneursym repair which is the most risky procedure

Official Title
-----------------
Homemade Fenestrated Physician-modified Stent-grafts for Arch Aortic Degenerative Aneurysm

Conditions
-----------------
Aortic Arch Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - patients operated on in our department between 2000 and January 2020 for a thoracic endoprosthesis Exclusion Criteria: - Patient who reject the study protocol
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of retrograde aortic dissection | Rate of retrograde aortic dissection | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of endoleak | Rate of endoleak | day 1 | 
| Rate of stroke | Rate of stroke | day 1 | 
| Rate of Mortality | Mortality | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proximal descending aorta aneurism, Proximal and distal neck (length >20mm et diameter >20mm and <40mm, thoracic endovascular aortic repair, Intra-abdominal septic complications